trial
as of 2026-07-01Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
NCTId NCT04959032
at a glance
Phase 3 · Completed
Enrollment 228 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2024-07-25
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
228 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-07-08
Primary completion
2024-07-25
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Indications
Sponsors
Intra-Cellular Therapies, Inc.Lead Sponsor
Sites
43 total
Little Rock, United StatesBellflower, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesMontclair, United StatesOrange, United StatesHollywood, United StatesMiami Lakes, United StatesOakland Park, United StatesAtlanta, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
228
Phase
PHASE3
Primary Completion Date
2024-07-25
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
indication
indication
indication